GlassScriptPhysician profile
Danielle Marie Hansen
NPI 1548436389
$5,374.50
in general payments reported to CMS, 2019-2025
51 companies · $543 in 2025
The $543 reported for 2025 was more than what 80% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $77.97 · 2021: $414 · 2022: $1,351 · 2023: $1,308 · 2024: $1,141 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,842 · Travel and Lodging: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,842.29 |
| Travel and Lodging | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,096.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $656.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $314.20 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Pfizer INC. | $253.67 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.25 | 2019-2023 | Jardiance, Synjardy |
| Baxter Healthcare | $196.07 | 2024 | Hillrom - Centrella Smart+ Bed |
| Amgen INC. | $162.62 | 2019-2025 | Evenity, Aimovig, Prolia |
| Eisai INC. | $157.29 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $154.61 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Galderma Laboratories, L.P. | $147.64 | 2024 | Aklief |
| Abbott Laboratories | $125.42 | 2020-2025 | Proclaim, Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $117.50 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $115.65 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $104.03 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $95.44 | 2019-2024 | Ingrezza |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.